Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Maria-Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela Garcia Garcia-Porrero, Miguel Jesús Villanueva Forero, Rafael Rios Tamayo, Antonia Sampol Mayol, Eugenio Gimenez, Jose-Angel Hernandez Rivas, Savana Research Group, Joaquín Martínez-Lopez

Blood (2024) 144 (Supplement 1): 7878.

https://doi.org/10.1182/blood-2024-206018

Published: 2024

Journal Articles

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Blood (2024) 144 (Supplement 1): 7012.

https://doi.org/10.1182/blood-2024-200679

Published: 2024

Journal Articles

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Blood (2024) 144 (Supplement 1): 5164.

https://doi.org/10.1182/blood-2024-205945

Published: 2024

Journal Articles

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Blood (2024) 144 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2024-197940

Published: 2024

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Blood (2023) 142 (Supplement 1): 645.

https://doi.org/10.1182/blood-2023-182964

Published: 2023

Journal Articles

Clonal Architecture and Evolution of Waldenström's Macroglobulinemia at the Single Cell Level

Cristina Jiménez, María García-Álvarez, Miguel Alcoceba, Alejandro Medina, Elham Askari, Veronica Gonzalez-Calle, Maria Casanova, Fernando Escalante Barrigón, M Eugenia Sarasquete, Marcos González Díaz, María Carmen Chillón Santos, Ramón García-Sanz

Blood (2022) 140 (Supplement 1): 3510–3511.

https://doi.org/10.1182/blood-2022-163057

Published: 2022

Journal Articles

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Catarina Maia, Noemi Puig, Cristina Pérez Ruiz, Maria Teresa Cedena Romero, Camila Guerrero, Marta Larrayoz, Cirino Botta, Norma C. Gutierrez, María José Calasanz, Maria Luisa Martin-Ramos, Miguel Hernández, Laura Rosinol Dachs, Esther González Garcia, Felipe De Arriba, Albert Oriol, Veronica Gonzalez-Calle, Fernando Escalante, Javier de la Rubia, Mercedes Gironella Mesa, Rafael Rios, Ricarda Belen Garcia Sanchez, Jose Maria Arguiñano PEREZ, Adrian Alegre, Jesus Martin, María del Carmen Couto Caro, Maria Casanova, Mario Arnao Herraiz, Ernesto Pérez, Sebastián Garzón López, Marta Sonia Gonzalez Perez, Guillermo Martín-Nuñez, Adriana Rossi, Morton Coleman, Cristina Encinas, Ana M. Vale, Ana Isabel Teruel, María Cortés Rodríguez, Jose A. Martinez-Climent, Juan-José Lahuerta, Joan Bladé Creixenti, Ruben Niesvizky, Jesús San-Miguel, Maria-Victoria Mateos, Bruno Paiva

Blood (2022) 140 (Supplement 1): 4200–4203.

https://doi.org/10.1182/blood-2022-163058

Published: 2022

Journal Articles

Clinical and Demographic Characteristics of Multiple Myeloma Patients at Study Enrollment: Analysis of Doriant Study (NCT:04659798)

Carmen Montes Gaisan, Buenaventura Buendía, Fernando Escalante, Esther Gonzalez Garcia, Marta Grande, Andrea Naves, Jesús Aparicio, Mercedes Gironella

Blood (2022) 140 (Supplement 1): 12528–12529.

https://doi.org/10.1182/blood-2022-157518

Published: 2022

Journal Articles

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Malin Hultcrantz, David Kleinman, Ravi Vij, Fernando Escalante, Nirali Kotowsky, Jacopo Bitetti, Christine Mackay, Natalie Boytsov, Leena Camadoo-O'Byrne, Guillaume Germain, Mei Sheng Duh, François Laliberté, Malena Mahendran, Ana Urosevic, Hans C. Lee

Blood (2022) 140 (Supplement 1): 10124–10126.

https://doi.org/10.1182/blood-2022-164929

Published: 2022

Journal Articles

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Blood (2022) 140 (Supplement 1): 4315–4317.

https://doi.org/10.1182/blood-2022-158538

Published: 2022

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Blood (2022) 140 (Supplement 1): 292–294.

https://doi.org/10.1182/blood-2022-159606

Published: 2022

Journal Articles

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

David F. Moreno, Cristina Jiménez, Fernando Escalante Barrigón, Elham Askari, Mario Arnao, Ángela Heredia, Magdalena Alcalá, Arancha Bermúdez, Ana Saus Carreres, Maria Casanova, Luis Palomera, Cristina Motllo, Ricarda Belen Garcia Sanchez, Ramón García-Sanz, Carlos Fernández De Larrea

Blood (2022) 140 (Supplement 1): 259–260.

https://doi.org/10.1182/blood-2022-163008

Published: 2022

Journal Articles

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Sudeep Karve, Shaji Kumar, Veronica Gonzalez De La Calle, Silvia Mangiacavalli, Chang-Ki Min, Efstathios Kastritis, Graca Esteves, Michel Delforge, Fernando Escalante, Jin Lu, Yang Liu, Max Bittrich, Charalampia Kyriakou, Andrew J. Yee, Emma Arriola, Jeremy A. Ross, Shivaji Manthena, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 3803.

https://doi.org/10.1182/blood-2021-149336

Published: 2021

Journal Articles

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Blood (2021) 138 (Supplement 1): 2719.

https://doi.org/10.1182/blood-2021-149192

Published: 2021

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

Blood (2021) 138 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2021-148423

Published: 2021

Journal Articles

ECOG Performance Status Shows a Stronger Association with Treatment Tolerability Than Some Multidimensional Scales in Elderly Patients Diagnosed with Hematological Malignancies

Fernando Ramos, MDPhD, Marta Castellanos, MD, Natalia De las Heras, MD, Fernando Escalante, MD, Silvia Fernandez-Ferrero, MDPhD, Maria Jesus Vidal, MD, Maria Lavinia Villalobos, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-136732

Published: 2020

Journal Articles

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-140934

Published: 2020

NARROW

Real-World Evidence of First-Line Therapy in Non-Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Comparative Effectiveness of Linvoseltamab Versus Current Real-World (RW) Standard-of-Care (SOC) Therapies in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM): Key Subgroups Analysis

Real-World Evidence of First-Line Therapy in Transplant Eligible Multiple Myeloma Patients: Insights from the Cimma Study

Determining Outcome in IgM Gammopathies: Integration of Molecular, Flow Cytometry and Clinical Factors in an International, Multicenter Series (the SAL-TO Study)

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Isolated and Dynamic Peripheral Blood Residual Disease Status Characterized By Mass Spectrometry Predicts Outcome in Patients with High Risk Smoldering Multiple Myeloma Treated in the GEM-CESAR Trial

Clonal Architecture and Evolution of Waldenström's Macroglobulinemia at the Single Cell Level

Immune Biomarkers of Survival and Severe Infection in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with the Backbone Regimen Lenalidomide and Dexamethasone (Rd)

Clinical and Demographic Characteristics of Multiple Myeloma Patients at Study Enrollment: Analysis of Doriant Study (NCT:04659798)

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. Experience with a Spanish Cohort

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Progression Risk and Long-Term Survival Trends of 915 Patients with Asymptomatic IgM Monoclonal Gammopathy

Pomalidomide-Dexamethasone Effectiveness in t(11;14) Positive Relapsed Multiple Myeloma in Real-World Setting

Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

ECOG Performance Status Shows a Stronger Association with Treatment Tolerability Than Some Multidimensional Scales in Elderly Patients Diagnosed with Hematological Malignancies

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only